by Admin | Jul 14, 2022 | Press Releases
ELUSYS THERAPEUTICS RECEIVES HEALTH CANADA APPROVAL FOR ANTHIM® FOR THE TREATMENT OF INHALATION ANTHRAX PARSIPPANY, NJ, AUGUST 12, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for...
by Admin | Jul 14, 2022 | Press Releases
OBILTOXAXIMAB RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF INHALATION ANTHRAX European Commission Decision Anticipated in November 2020 PARSIPPANY, NJ, OCTOBER 8, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that the Committee for Medicinal...
by Admin | Jul 14, 2022 | Press Releases
OBILTOXAXIMAB RECEIVES MARKETING AUTHORIZATION FROM EUROPEAN COMMISSION FOR THE TREATMENT OF INHALATION ANTHRAX PARSIPPANY, NJ, DECEMBER 2, 2020 – Elusys Therapeutics, Inc. (Elusys) today announced that the European Commission has approved obiltoxaximab, the company’s...
by Admin | Jul 14, 2022 | Press Releases
ELUSYS THERAPEUTICS FINALIZES HHS CONTRACT TO DELIVER ANTHIM®, ITS TREATMENT FOR INHALATION ANTHRAX, TO THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Completed first phase of contract for $50 million; HHS options to procure up to $31 million of ANTHIM by the first...
